Evidence map›Paper›PMID 32440473›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020

Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer.

Ahmed M E Abdalla, Lin Xiao, Yu Miao, Lixia Huang, Gendeal M Fadlallah, Mario Gauthier, Chenxi Ouyang, Guang Yang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Nanomodified Switch Induced Precise and Moderate Activation of CAR-T Cells for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  12. Emerging Progress of RNA-Based Antitumor Therapeutics.International journal of biological sciences · 2023
    Review
  13. Biomaterials promoteFrontiers in immunology · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Ahmed M E AbdallaDepartment of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China.
Lin XiaoDepartment of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China.
Yu MiaoDepartment of Vascular Surgery General Hospital of Ningxia Medical University Yinchuan 750004 China.
Lixia HuangHubei Key Laboratory of Purification and Application of Plant Anti-Cancer Active Ingredients School of Chemistry and Life Sciences Hubei University of Education Wuhan 430205 China.
Gendeal M FadlallahDepartment of Chemistry and Biology Faculty of Education University of Gezira Wad-Medani 2667 Sudan.
Mario GauthierDepartment of Chemistry University of Waterloo Waterloo N2L 3G1 Canada.
Chenxi OuyangDepartment of Vascular Surgery Fuwai Hospital National Center for Cardiovascular Disease Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100037 China.
Guang YangDepartment of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China.ORCID https://orcid.org/0000-0001-9198-3556
Huazhong University of Science and Technology · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHubei University of Education · CNNingxia Medical University · CNUniversity of Bahri · SDUniversity of Gezira · SDUniversity of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing experience with engineered chimeric antigen receptor (CAR)-T cells has revealed some of the challenges associated with developing patient-specific therapy. The promising clinical results obtained with CAR-T therapy nevertheless demonstrate the urgency of advancements to promote and expand its uses. There is indeed a need to devise novel methods to generate potent CARs, and to confer them and track their anti-tumor efficacy in CAR-T therapy. A potentially effective approach to improve the efficacy of CAR-T cell therapy would be to exploit the benefits of nanotechnology. This report highlights the current limitations of CAR-T immunotherapy and pinpoints potential opportunities and tremendous advantages of using nanotechnology to 1) introduce CAR transgene cassettes into primary T cells, 2) stimulate T cell expansion and persistence, 3) improve T cell trafficking, 4) stimulate the intrinsic T cell activity, 5) reprogram the immunosuppressive cellular and vascular microenvironments, and 6) monitor the therapeutic efficacy of CAR-T cell therapy. Therefore, genetic and functional modifications promoted by nanotechnology enable the generation of robust CAR-T cell therapy and offer precision treatments against cancer.

Indexed as

cancer immunotherapychimeric antigen receptor T cell therapynanotechnologyT cell engineering

Identifiers

PMID32440473
PMCPMC7237845
OpenAlexW3006716329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.